Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 6Neoplasms 5Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Vomiting 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nausea 1NSCLC 1Mucositis 1Mastocytosis, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

Rituximab 117Cyclophosphamide 104fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Cytarabine 47Etoposide 44Mycophenolic Acid 41Filgrastim 40Whole-Body Irradiation 37Tacrolimus 36Melphalan 35Bortezomib 34Methotrexate 33Cyclosporine 33Busulfan 31Radiotherapy 30Vincristine 28Doxorubicin 27Dexamethasone 27Carmustine 25Antilymphocyte Serum 25Lenalidomide 23Bendamustine Hydrochloride 23ibrutinib 22Granulocyte Colony-Stimulating Factor 20obinutuzumab 18fludarabine 18acalabrutinib 18Prednisone 18venetoclax 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Mantle-Cell × Diphenhydramine × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡